NCT02334748View on ClinicalTrials.gov

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 3, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Systemic Juvenile Idiopathic ArthritisHereditary Periodic Fevers
Interventions
DRUG

canakinumab

canakinumab

Trial Locations (3)

69677

Novartis Investigative Site, Bron

75015

Novartis Investigative Site, Paris

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY